Evolutionary prediction of medicinal properties in the genus Euphorbia L

• Published in: Scientific reports Vol. 6; no. 1; p. 30531
• Main Authors: Ernst, Madeleine, Saslis-Lagoudakis, C. Haris, Grace, Olwen M., Nilsson, Niclas, Simonsen, Henrik Toft, Horn, James W., Rønsted, Nina
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.07.2016; Nature Publishing Group
• Subjects: 45/23; 631/154/1435; 631/181/757; Ethnobotany - methods; Euphorbia - classification; Humanities and Social Sciences; Humans; Inflammation - drug therapy; Medicine, Traditional - methods; multidisciplinary; Phylogeny; Phytotherapy; Plants, Medicinal - classification; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep30531

The current decrease of new drugs brought to the market has fostered renewed interest in plant-based drug discovery. Given the alarming rate of biodiversity loss, systematic methodologies in finding new plant-derived drugs are urgently needed. Medicinal uses of plants were proposed as proxy for bioactivity, and phylogenetic patterns in medicinal plant uses have suggested that phylogeny can be used as predictive tool. However, the common practice of grouping medicinal plant uses into standardised categories may restrict the relevance of phylogenetic predictions. Standardised categories are mostly associated to systems of the human body and only poorly reflect biological responses to the treatment. Here we show that medicinal plant uses interpreted from a perspective of a biological response can reveal different phylogenetic patterns of presumed underlying bioactivity compared to standardised methods of medicinal plant use classification. In the cosmopolitan and pharmaceutically highly relevant genus Euphorbia L., identifying plant uses modulating the inflammatory response highlighted a greater phylogenetic diversity and number of potentially promising species than standardised categories. Our interpretation of medicinal plant uses may therefore allow for a more targeted approach for future phylogeny-guided drug discovery at an early screening stage, which will likely result in higher discovery rates of novel chemistry with functional biological activity.